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December 20111848 Abstractsor absence of vonWillebrand factor (vWF) may, in an animal model, protect
against brain infarction without increasing intercerebral hemorrhage despite
prolongation of bleeding time (Kleinschnitz C et al. Blood 2009;113:3600-
3). The authors sought to determine whether inhibition of vWFmay provide
efficacy with respect to potentially clinically relevant endpoints in patients
with cerebravascular disease.
ARC1779 is an aptamer inhibiting pro thrombotic function of vWF. It
blocks to the A-1 domain of vWF, blocking interaction with glycoprotein.
Aptamars are oligonucleotides that share some attributes of monoclonal
antibodies as well as some of those of low-molecular chemically synthesized
drugs. ARC1779 is aptamer that blocks the A1 domain of vWF and therefore
inhibits vWF factor dependant platelet function. The author’s investigated
the affect of ARC1779 on cerebral emboli following carotid endarterectomy
(CEA) in a randomized clinical trial. Following CEA, patients were random-
ized in a double blind fashion to receive ARC1779 or placebo. Cerebral
embolic signals were determined with transcranial Doppler for the first three
hours postoperatively. The primary endpoint was time to first embolic signal.
There were 36 patients recruited for the trial, 18 in each arm. The median
time, as determined by Kaplan-Meier methods, to first embolic signal was
83.6 minutes for ARC1779 compared with 5.5 minutes for placebo (P 
.007). Inhibition of vWF correlated with reduced embolic signals (P .03).
There was increased perioperative bleeding and anemia in the patients
treated with ARC1779.
Comment: This study introduces a new class of antithrombotic (ap-
tamer) and a new therapeutic mechanism (von Willebrand factor antago-
nism). The model of efficacy here was to reduce cerebral embolism after
CEA. However, whereas, embolic signals appear to be reduced with
ARC1799 there was one stroke in both ARC1779 group and in the placebo
group. There was one serious case of bleeding in the ARC1779 patients.
Additional work with truly meaningful reductions of clinically significant
endpoints without increased bleeding will be needed before one can con-
sider the use of an ARC1779 type drug in clinical practice.
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tConclusion: In patients with proven symptomatic pulmonary embo-
ism (PE) symptoms and signs of deep venous thrombosis (DVT) are present
nly in 1/3 of cases but aremore frequent whenDVT extends to the femoral
ein.
Summary:Deep venous thrombosis (DVT) and pulmonary embolism
PE) are clinical manifestations of venous thromboembolism (VTE). The
arge majority of cases of symptomatic PE (90%) are caused by lower limb
VT (Kearon C. Circulation 2003;107:122-30). Duplex is frequently used
s the first method to search for venous thrombosis in patients with sus-
ected PE or DVT. In addition, presence of DVT as diagnosed by duplex
ltrasound is independently associated with adverse outcome of PE (Wicki J.
hromb Haemost 2000;84:548-52). The authors sought to determine in
atients with a diagnosis of PE, whether clinical characteristics and throm-
osis site in lower extremity veins are able to predict PE extent. They
nalyzed 524 consecutive cases of proven symptomatic PE diagnosed be-
ween January 1996 and December 2006. The mean age of the patients was
1.1 years 14.4 years and 46.6% (n 244) were men. There were signs or
ymptoms of DVT in 30.9% of the patients. Duplex ultrasound was per-
ormed in 383 patients and DVT was found in 75.5% of those examined. In
4.1 % the identified DVT was in the poplietal or femoral vein. Signs or
ymptoms of DVT were predictors of a positive duplex ultrasound study
P .001). Signs and symptoms were associated with femoral vein DVT (P
.029). Medical illness (P .02), central venous catheter, (P .04), death
n hospital (P .032) predicted a negative duplex ultrasound study. Duplex
ltrasound findings and clinical findings were not associated with PE extent.
Comment: Sixty nine percent of the patients with proven PE had no
VT signs or symptoms of DVT on clinical examination and a positive
uplex ultrasound did not correlate with a major PE (P .98). Conversely,
VT was found in only 75.6% of patients with a proven PE. Ultrasound
xamination of the lower extremities in patients with suspected PE therefore
annot, by itself, rule out PE. However, lower extremity ultrasound may be
seful in that the concordance of lower extremity DVT with proven PE is
easonably high. There is also evidence to suggest that early compressive
herapy and mobilization of patients with acute DVT may decrease long
erm postphlebitic syndrome. Thus the reason to perform a duplex exami-
ation of the lower extremities in patients with suspected PE is not just to try
nd diagnose PE, but to diagnose DVT and potentially institute treatment
ther than just anticoagulation that is specifically directed to the DVT and
hat may reduce long term morbidity of DVT.
